ConductScience.org, home

Paper35802255

Mavacamten: First Approval.

Keam SJ. Drugs, 2022. Cited by 79 papers, by iCite.

Cite this record

ConductScience Library. Mavacamten: First Approval. Papers, record 35802255. Release papers-2026-11-12-0.1.0, 12 Nov 2026. https://conductscience.org/library/papers/35802255

Download JSON
Sources
11 sources
Release
papers-2026-11-12-0.1.0

Paper

PubMed's record of the paper, with iCite's citation figures. No abstract is shown.

Title
Mavacamten: First Approval.
PubMed
Journal
Drugs
PubMed
Year
2022
PubMed
Publication types
Journal Article, Review
PubMed
Citations, by iCite
79
iCite
Relative citation ratio, by iCite
6.32
iCite
Revised in PubMed
2025-07-28
PubMed

Authors1

The authors in the order PubMed's record lists them, with the ORCID iDs it states.

OrderAuthorForenameKindORCID iD
1Keam SJSusan J

Source PubMed

Download CSV of authors

Topics6

NLM's MeSH indexing of the paper, its major topics first.

MeSH termMajor
BenzylaminesMajor topic
Cardiomyopathy, HypertrophicMajor topic
Adult
Cardiac Myosins
Humans
Uracil

Comments and corrections1

PubMed's comments and corrections, NLM's own indexing: retractions first, then expressions of concern, errata and updates, and comments last.

KindPMIDTitleIn Papers
Erratum in35921035Correction to: Mavacamten: First Approval.https://conductscience.org/library/papers/35921035

Source PubMed

Download CSV of comments and corrections

References2

The papers the reference list in PubMed's record names, those in our copy of PubMed, in the list's order.

OrderPMIDTitleJournalYearIn PapersSource
130428294Clinical Course and Management of Hypertrophic Cardiomyopathy.N Engl J Med2018https://conductscience.org/library/papers/30428294PubMed
235435607The Impact of Mavacamten on the Pathophysiology of Hypertrophic Cardiomyopathy: A Narrative Review.Am J Cardiovasc Drugs2022https://conductscience.org/library/papers/35435607PubMed

Download CSV of references

Cited by52

The papers in our copy of PubMed whose reference list names this one, newest first. iCite, which reads more sources, counts 79 citations.

PMIDTitleJournalYearIn PapersSource
42911542Real-World Effectiveness of Mavacamten in Canada: Insights from the MAVEN Study.Cardiol Ther2026https://conductscience.org/library/papers/42911542PubMed
42405364Comprehensive Framework of Heart Failure with Preserved Ejection Fraction Management for Hospitalists: A Scoping Review.J Brown Hosp Med2026https://conductscience.org/library/papers/42405364PubMed
42327436Early Insights on Mavacamten Usage in Canada: A Retrospective Cohort Study of the Mavacamten Patient Support Program.CJC Open2026https://conductscience.org/library/papers/42327436PubMed
42160017Safety, tolerability, pharmacokinetics, pharmacodynamics and food effect of HRS-1893, a cardiac myosin inhibitor, in healthy subjects.Br J Clin Pharmacol2026https://conductscience.org/library/papers/42160017PubMed
41941083Aficamten: First Approval.Drugs2026https://conductscience.org/library/papers/41941083PubMed
41641607Efficacy and Safety of Mavacamten and Aficamten in Obstructive and Nonobstructive Hypertrophic Cardiomyopathy: A Systematic Review and Meta-Analysis.Crit Pathw Cardiol2026https://conductscience.org/library/papers/41641607PubMed
41375897Mavacamten for Obstructive Hypertrophic Cardiomyopathy: Targeting Sarcomeric Hypercontractility with Demonstrated Long-Term Safety and Efficacy-A Narrative Review.J Clin Med2025https://conductscience.org/library/papers/41375897PubMed
41174905Editorial: Hypertrophic Cardiomyopathy and Precision Medicine in Cardiovascular Disease.Med Sci Monit2025https://conductscience.org/library/papers/41174905PubMed
41043917Cardiogenic Shock in Hypertrophic Cardiomyopathy Treated With Mavacamten and Clarithromycin.JACC Case Rep2025https://conductscience.org/library/papers/41043917PubMed
40867543Cardiac Myosin Inhibitors in the Treatment of Hypertrophic Cardiomyopathy: Clinical Trials and Future Challenges.Biomolecules2025https://conductscience.org/library/papers/40867543PubMed
40852491Early Detection of Treatment Response to Mavacamten in Hypertrophic Obstructive Cardiomyopathy With Severe Mitral Regurgitation Using Magnetocardiography.Clin Case Rep2025https://conductscience.org/library/papers/40852491PubMed
40708763A Systematic Review of Clinical Trials on Mavacamten in Hypertrophic Cardiomyopathy.Heart Int2025https://conductscience.org/library/papers/40708763PubMed
40624601Cardiac myosin inhibitors in hypertrophic cardiomyopathy.J Cardiovasc Imaging2025https://conductscience.org/library/papers/40624601PubMed
40515800Unveiling the complexity of nonobstructive hypertrophic cardiomyopathy.Heart Fail Rev2025https://conductscience.org/library/papers/40515800PubMed
40500110Cardiac myosin inhibitors: a silver lining for an old disease.Open Heart2025https://conductscience.org/library/papers/40500110PubMed
40488145Reduction in myofilament Ca2+ sensitivity partially ameliorates the cardiac phenotype in hypertrophic cardiomyopathy linked to a TnT-R92Q mutation.Front Physiol2025https://conductscience.org/library/papers/40488145PubMed
40400802Mavacamten Cardiac Myosin Inhibitor: Clinical Applications and Future Perspectives.Cureus2025https://conductscience.org/library/papers/40400802PubMed
40306862Experimental Models of Hypertrophic Cardiomyopathy: A Systematic Review.JACC Basic Transl Sci2025https://conductscience.org/library/papers/40306862PubMed
40246577Tale of three services: early UK experience with mavacamten treatment for hypertrophic cardiomyopathy with left ventricular outflow tract obstruction.Open Heart2025https://conductscience.org/library/papers/40246577PubMed
40169351Real-World Experience of Mavacamten for Patients With Obstructive Hypertrophic Cardiomyopathy in South Korea: A Prospective Multi-Center Observational Study.Korean Circ J2025https://conductscience.org/library/papers/40169351PubMed

See all 52 cited byDownload CSV of cited by

Genes14

The genes the Gene search release ties to the paper: Swiss-Prot's references first, then PubTator's text mining.

Download CSV of genes

Data dates

The date of each source this release read.

PubMed
2026-11-06
PubMed
iCite
2026-11-05
iCite
PMC's ID file
2026-11-05
PMC's ID file
NIH RePORTER's grant and paper links
2026-11-01
NIH RePORTER's grant and paper links
Trials
2026-11-12
Gene search
2026-11-11
Pipelines
2026-09-18

None in this release

  • Grants
  • Trials
  • Drugs
  • Data

Sources 11

  • ChEMBL, through Open TargetsCC BY-SA 3.0
  • ClinicalTrials.govNo license stated
  • HGNCCC0
  • iCiteCC BY 4.0
  • NCBI GenePublic domain (US government)
  • NIH RePORTER's grant and paper linksPublic domain
  • Open TargetsCC0 1.0
  • PMC's ID filePublic domain (US government)
  • PubMedNLM's terms
  • PubTator 3Public domain
  • UniProtCC BY 4.0
Each source's terms
  • ChEMBL, through Open TargetsCC BY-SA 3.0, for the parts from ChEMBL. Read on 8 Nov 2026 at https://platform-docs.opentargets.org/licence
  • ClinicalTrials.govnone stated
  • HGNCCC0: https://www.genenames.org/about/license/
  • iCiteCC BY 4.0
  • NCBI GeneNone named for the file. NCBI says information created by or for the US government on its site is in the public domain, and asks that NLM be acknowledged: https://www.ncbi.nlm.nih.gov/home/about/policies/
  • NIH RePORTER's grant and paper linksPublic domain (NIH RePORTER)
  • Open TargetsCC0 1.0. Open Targets asks that users cite its latest paper: Buniello et al. 2025, Open Targets Platform: facilitating therapeutic hypotheses building in drug discovery, Nucleic Acids Research 53(D1):D1467, PMID 39657122. Read on 8 Nov 2026 at https://platform-docs.opentargets.org/licence
  • PMC's ID fileNone named for the file. NCBI says information created by or for the US government on its site is in the public domain, and asks that NLM be acknowledged: https://www.ncbi.nlm.nih.gov/home/about/policies/
  • PubMedNLM's terms
  • PubTator 3Public domain
  • UniProtCC BY 4.0. UniProt's licence file: "All databases and documents in the UniProt FTP directory may be copied and redistributed freely, without advance permission, provided that this copyright statement is reproduced with each copy." UniProt asks that users cite its latest paper: The UniProt Consortium, UniProt: the Universal Protein Knowledgebase in 2025, Nucleic Acids Research 53:D609-D617, https://doi.org/10.1093/nar/gkae1010. Read on 9 Nov 2026 at https://www.uniprot.org/help/license

ClinicalTrials.gov's data carry an international copyright outside the United States: https://clinicaltrials.gov/about-site/terms-conditions.

For software

Read this paper from software.

The record and each of its lists are JSON, twenty rows a page. No key.

GET https://conductscience.org/api/papers/v1/35802255

GET https://conductscience.org/api/papers/v1/35802255/cited_by?page=2